Karyopharm Enters Material Agreement, Sells Unregistered Equity

Ticker: KPTI · Form: 8-K · Filed: Mar 24, 2026 · CIK: 0001503802

Karyopharm Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyKaryopharm Therapeutics Inc. (KPTI)
Form Type8-K
Filed DateMar 24, 2026
Risk Levelmedium
Pages12
Reading Time14 min
Key Dollar Amounts$0.0001, $6.785, $6.7849, $10.00, $30 million
Sentimentmixed

Complexity: moderate

Sentiment: mixed

Topics: equity-offering, capital-raise, material-agreement, dilution

TL;DR

**Karyopharm just raised capital via private stock sales, expect potential dilution.**

AI Summary

Karyopharm Therapeutics Inc. filed an 8-K on March 24, 2026, detailing an entry into a material definitive agreement and unregistered sales of equity securities. This indicates the company is likely raising capital through private stock sales, which could dilute existing shareholders but also fund future operations or research. For investors, this matters because while it provides capital, the dilution could impact the value of their current holdings.

Why It Matters

This filing signals Karyopharm is securing new funding, which is crucial for a biotech company, but the method of unregistered equity sales could dilute existing shareholder value.

Risk Assessment

Risk Level: medium — The sale of unregistered equity can lead to dilution for current shareholders, creating uncertainty about future stock performance.

Analyst Insight

A smart investor would investigate the terms of the 'Material Definitive Agreement' and the specifics of the 'Unregistered Sales of Equity Securities' to understand the extent of potential dilution and the purpose of the capital raise before making any investment decisions.

Key Players & Entities

  • Karyopharm Therapeutics Inc. (company) — the filer of the 8-K
  • 0001503802 (company) — CIK of Karyopharm Therapeutics Inc.
  • 2026-03-24 (date) — filing date and period of report

FAQ

What specific items were reported in Karyopharm Therapeutics Inc.'s 8-K filing on March 24, 2026?

The 8-K filing by Karyopharm Therapeutics Inc. on March 24, 2026, reported Item 1.01: Entry into a Material Definitive Agreement and Item 3.02: Unregistered Sales of Equity Securities, among other items like Regulation FD Disclosure and Other Events.

What is the significance of Item 3.02: Unregistered Sales of Equity Securities for Karyopharm Therapeutics Inc.?

Item 3.02, Unregistered Sales of Equity Securities, indicates that Karyopharm Therapeutics Inc. has sold shares of its stock without registering them with the SEC, typically to a limited number of investors, which can be a way to raise capital quickly but often results in dilution for existing shareholders.

Filing Stats: 3,573 words · 14 min read · ~12 pages · Grade level 14.4 · Accepted 2026-03-24 08:00:37

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
  • $6.785 — "Common Stock"), at a purchase price of $6.785 per share and, in lieu of Common Stock,
  • $6.7849 — unded Warrants") at a purchase price of $6.7849 per pre-funded warrant, and (ii) accomp
  • $10.00 — Common Stock with an exercise price of $10.00 per share (the "Common Stock Warrants")
  • $30 million — sult in gross proceeds of approximately $30 million at closing to the Company, before place
  • $44 million — ill receive an additional approximately $44 million of gross proceeds if the accompanying C
  • $9.6 million — of sales commissions, of approximately $9.6 million. As of March 23, 2026, the Company had

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant to Purchase Common Stock 4.2 Form of Warrant to Purchase Common Stock 10.1* Securities Purchase Agreement, dated March 24, 2026, by and between the Company and the Investor 10.2 Form of Registration Rights Agreement 99.1 Press Release issued by Karyopharm Therapeutics Inc. on March 24, 2026 99.2 Corporate Presentation issued by Karyopharm Therapeutics Inc. on March 24, 2026 99.3 Press Release issued by Karyopharm Therapeutics Inc. on March 24, 2026 104 Cover Page Interactive Data File (formatted as Inline XBRL) * Certain exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: March 24, 2026 By: /s/ Michael Mano Michael Mano Executive Vice President, Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.